[{"id":"a8eb30bd-0fe3-47c6-8e1f-dbc91b74bace","acronym":"ARCITECT","url":"https://clinicaltrials.gov/study/NCT05928806","created_at":"2023-07-03T16:10:37.286Z","updated_at":"2025-02-25T13:41:35.328Z","phase":"Phase 2","brief_title":"Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial","source_id_and_acronym":"NCT05928806 - ARCITECT","lead_sponsor":"Michael B. Atkins, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 10/10/2025","primary_completion_date":" 10/10/2025","study_txt":" Completion: 10/12/2026","study_completion_date":" 10/12/2026","last_update_posted":"2025-02-21"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"dc334b0f-8b5c-4b2f-8468-f243cf63a6a0","acronym":"NCI-2022-09458","url":"https://clinicaltrials.gov/study/NCT05627635","created_at":"2022-11-25T15:58:22.182Z","updated_at":"2025-02-25T15:20:07.740Z","phase":"Phase 1/2","brief_title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05627635 - NCI-2022-09458","lead_sponsor":"City of Hope Medical Center","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2025-02-12"},{"id":"d6a707a3-bb85-4ce5-8066-8bc03501bcf5","acronym":"C-800-01","url":"https://clinicaltrials.gov/study/NCT03860272","created_at":"2023-03-25T19:00:32.588Z","updated_at":"2025-02-25T16:37:22.836Z","phase":"Phase 1","brief_title":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","source_id_and_acronym":"NCT03860272 - C-800-01","lead_sponsor":"Agenus Inc.","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 499","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/13/2025","primary_completion_date":" 01/13/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"80af2132-83d6-4705-a7c2-701bcc6ce4a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06336902","created_at":"2024-03-29T16:39:58.679Z","updated_at":"2025-02-25T17:03:18.664Z","phase":"Phase 1","brief_title":"Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06336902","lead_sponsor":"University of Southern California","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/15/2025","start_date":" 01/15/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-03"},{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"6a7437dd-1b7b-49b8-8341-ff9ad04a3230","acronym":"C-800-25","url":"https://clinicaltrials.gov/study/NCT05608044","created_at":"2022-11-08T15:56:56.796Z","updated_at":"2024-07-02T16:34:59.296Z","phase":"Phase 2","brief_title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","source_id_and_acronym":"NCT05608044 - C-800-25","lead_sponsor":"Agenus Inc.","biomarkers":" EGFR • BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["EGFR • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-04"},{"id":"17124774-125f-48f3-9fa4-bdffab757f3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06300463","created_at":"2024-03-12T14:20:52.081Z","updated_at":"2024-07-02T16:35:09.965Z","phase":"Phase 2","brief_title":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT06300463","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-12"},{"id":"6003592e-c212-4e12-bf84-ded1b1c44edb","acronym":"CIME","url":"https://clinicaltrials.gov/study/NCT06346197","created_at":"2024-04-03T23:39:52.167Z","updated_at":"2024-07-02T16:35:11.577Z","phase":"Phase 3","brief_title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","source_id_and_acronym":"NCT06346197 - CIME","lead_sponsor":"Centre Leon Berard","biomarkers":" TMB • LAG3 • TIGIT","pipe":"","alterations":" ","tags":["TMB • LAG3 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/15/2028","primary_completion_date":" 05/15/2028","study_txt":" Completion: 05/15/2028","study_completion_date":" 05/15/2028","last_update_posted":"2024-04-03"},{"id":"0e1c63e1-f6de-4d37-9ced-a5cce7ed01f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318469","created_at":"2022-04-08T21:52:57.367Z","updated_at":"2024-07-02T16:35:12.029Z","phase":"Phase 1/2","brief_title":"Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT05318469","lead_sponsor":"Yuan Yuan","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • balstilimab (AGEN2034)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-02"},{"id":"06240d3a-65df-4d82-9307-690aa6491b9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529316","created_at":"2022-09-07T16:55:49.888Z","updated_at":"2024-07-02T16:35:23.516Z","phase":"Phase 2","brief_title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","source_id_and_acronym":"NCT05529316","lead_sponsor":"Agenus Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Suspended","enrollment":" Enrollment 220","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-01-12"},{"id":"307f58ff-e40c-4fdc-bf96-004db83003a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06076837","created_at":"2023-10-11T16:12:25.578Z","updated_at":"2024-07-02T16:35:33.893Z","phase":"Phase 1","brief_title":"The Seven Trial: Exploiting the Unfolded Protein Response","source_id_and_acronym":"NCT06076837","lead_sponsor":"HonorHealth Research Institute","biomarkers":" CEACAM5 • MUC16","pipe":"","alterations":" ","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-11"},{"id":"3be93e43-e025-47ec-8e3e-e3ce079cd408","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891821","created_at":"2023-06-07T14:07:49.216Z","updated_at":"2024-07-02T16:35:35.532Z","phase":"Phase 2","brief_title":"Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)","source_id_and_acronym":"NCT05891821","lead_sponsor":"Immune Oncology Research Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2023-09-27"},{"id":"119219a5-41c8-4ccd-b3d3-65d472efd573","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672316","created_at":"2023-01-05T14:58:30.826Z","updated_at":"2024-07-02T16:35:41.799Z","phase":"Phase 1/2","brief_title":"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy","source_id_and_acronym":"NCT05672316","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 11/09/2024","primary_completion_date":" 11/09/2024","study_txt":" Completion: 11/09/2024","study_completion_date":" 11/09/2024","last_update_posted":"2023-07-27"},{"id":"748001fe-e389-4c5d-ac32-564f6f6a6a83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05205330","created_at":"2022-01-25T16:54:18.183Z","updated_at":"2024-07-02T16:35:51.992Z","phase":"Phase 1/2","brief_title":"A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT05205330","lead_sponsor":"Rottapharm Biotech","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type • RAS mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • vorbipiprant (CR6086)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 11/23/2021","start_date":" 11/23/2021","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-29"},{"id":"4b5451e3-0df3-4891-afbe-051a7575e8b3","acronym":"BRAVA","url":"https://clinicaltrials.gov/study/NCT04943627","created_at":"2021-06-29T17:53:25.885Z","updated_at":"2024-07-02T16:36:02.973Z","phase":"Phase 3","brief_title":"Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)","source_id_and_acronym":"NCT04943627 - BRAVA","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • balstilimab (AGEN2034)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/22/2021","primary_completion_date":" 10/22/2021","study_txt":" Completion: 10/22/2021","study_completion_date":" 10/22/2021","last_update_posted":"2022-10-05"},{"id":"996d882f-fae7-40b0-9fb5-12daec76b9ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607200","created_at":"2021-01-19T20:31:41.807Z","updated_at":"2024-07-02T16:36:18.687Z","phase":"Phase 2","brief_title":"AGEN2034 \u0026 AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma","source_id_and_acronym":"NCT04607200","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • zalifrelimab (UGN-301)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 09/13/2021","primary_completion_date":" 09/13/2021","study_txt":" Completion: 09/13/2021","study_completion_date":" 09/13/2021","last_update_posted":"2022-01-11"}]